Implementing Partners
USAID implements its foreign assistance activities by utilizing the expertise of other key federal agencies, as well as contributing to programs or purchasing services of U.S. organizations and companies. USAID utilizes cooperative agreements (CAs) and contracts to achieve results that contribute to the Agency's performance goals. USAID also partners with international organizations to implement global health activities. In addition to partnering directly with international organizations to accomplish specific objectives, USAID collaborates and coordinates with other donor organizations in the field to maximize the effectiveness of its global health programs. Through USAID's Bureau for Global Health (GH), the following implementing mechanisms provide support to USAID's global TB programs:
Centers
for Disease Control and Prevention (CDC) Interagency Agreement (IAA)
(Awarded 8/2006; completion date 9/30/2011)
The objective of the CDC IAA is to strengthen the delivery of infectious disease programs and other health programs in developing countries by accessing technical expertise. Specific areas of work include technical and program support for the development and implementation of appropriate global, regional/country-level programs and strategies; and studies, assessments, and evaluation and other research activities to assist in policy dialogue, planning, and formulating health programs. While CDC possesses expertise in all aspects of TB control, they are particularly strong in the following areas: operations research, epidemiology and data analysis, information systems, infection control, laboratories, surveillance and treatment of MDR-TB, and interventions to address TB-HIV/AIDS co-infection. The Agreement Officer’s Technical Representative is Teresa Bernhard.
Child Survival & Health Grants Program (CSHGP)
(Award and completion dates vary by cooperative agreement)
CSHGP supports community-based health programs implemented by U.S. private voluntary organizations (PVOs) and their local partners. The program draws on PVOs’ experience with community-based programs to implement activities to strengthen TB services and to engage communities in supporting TB patients and in advocacy, communications, and social mobilization. Grants are ongoing in several countries, including South Africa, Indonesia, the Malawi, Zambia, India, and Mozambique. The Agreement Officer’s Technical Representative is Ashley Gelman, and Cheri Vincent serves as the TB Resource Person.
Global Alliance for TB Drug Development
(Awarded 9/2008; completion date 9/2013)
The Global Alliance for TB Drug Development (TB Alliance) is a nonprofit public-private partnership that seeks to develop new tuberculosis drugs that can shorten treatment duration and simplify tuberculosis treatment, treat multidrug-resistant (MDR-)TB, and be used simultaneously with antiretroviral drugs (ARVs). The Agreement Officer’s Technical Representative is Christy Hanson.
IFRC Malaria and TB Grant
(Awarded 9/2008; completion date 9/2013)
USAID supports IFRC TB activities in Kazakhstan, South Africa, and India. IFRC works to raise awareness and increase care, and support for vulnerable populations affected with MDR TB. Activities are implemented by the respective national societies and supports volunteers and Red Cross nurses to provide treatment support to MDR TB patients to reduce patient default and increase treatment completion. The project raises awareness of TB symptoms and treatment among vulnerable groups. Volunteers and nurses will receive additional or refresher training in TB, MDR TB, and TB/HIV, disseminate IEC materials, and conduct educational campaigns. The Agreement Officer's Technical Representative is Laura Andes and the TB Technical Advisor is Carolyn Mohan.
Stop TB Partnership and the Global TB Drug Facility (GDF)
(Awarded 9/2008; completion date 9/2013)
The Stop TB Partnership is an association of more than 1,300 organizations worldwide dedicated to defeating TB. It includes high-burden countries, donors, technical and research institutions, nongovernmental organizations, the private sector, and community groups. It is the leading institution worldwide for international TB. The Bureau for Global Health provides funding through the Stop TB Partnership grant for activities, including support for the Civil Society Challenges grants; crosscutting social mobilization and advocacy activities; and other Stop TB Partnership technical working group activities. Through this grant, USAID also provides funding to the Global TB Drug Facility (GDF) to support grants for TB drugs to countries in need and to support the GDF’s direct procurement mechanism. The Agreement Officer’s Technical Representative for the grant to Stop TB is Christy Hanson.
Strengthening Pharmaceutical Systems (SPS)
(Awarded 6/2007; completion date 7/2012)
The SPS program provides technical leadership to improve access to health commodities and promote their appropriate use. In the area of TB, SPS has expertise in assessing TB commodity management systems and in developing and implementing improvement strategies for product selection, forecasting, procurement, distribution and use, laboratory services, information systems, and monitoring and evaluation. SPS provides technical assistance and promotes capacity development in pharmaceutical management to USAID Mission country programs, national TB programs, the GDF, the Green Light Committee, and the Stop TB and TB CAP partners. The Contracting Officer’s Technical Representative is Anthony Boni.
TB CARE I & II
(Awarded 10/1/2010; completion date 9/30/2015)
Following on the success of the TB CAP project, GH/HIDN has issued two 5-year awards, TB CARE I and TB CARE II, designed to improve the quality of and access to TB prevention, diagnosis and treatment, improve coordination of TB/HIV activities, improve MDR TB prevention, diagnosis and treatment, and strengthen TB systems as they relate to the overall health care system.
TB CARE I will be implemented by the TBCTA consortium, led by KNCV as the prime recipient. TBCTA is a partnership of seven organizations; American Thoracic Society (ATS), Family Health International (FHI), Japan Anti-Tuberculosis Association (JATA), KNCV Tuberculosis Foundation (KNCV), Management Sciences for Health (MSH), International Union Against Lung and Tuberculosis Disease (The Union) and the World Health Organization (WHO).
TB CARE II will be implemented by URC as the prime recipient along with Jhpiego, Partners in Health, and Project HOPE along with the Canadian Lung Association.
TB CARE I and TB CARE II will both:
- Assist national programs to provide universal and early case detection
- Assist national programs to provide universal access to DST for suspected cases and treatment to all those with MDR TB cases
- Assist national programs to increase early case detection, expand intensified case finding, enhance airborne infection control efforts and expand access to and integrate treatment of TB and HIV in co-infected individuals
- Assist national programs to fully contribute to health system strengthening as it relates to TB, particularly for improving political commitment, strengthening human resources, enhancing health information and surveillance systems, infection control, and engaging all care providers
With the support of the TB CARE management team, the projects will coordinate their activities and work in a collaborative fashion. TB CARE I and TB CARE II can accept funds from a variety of budgetary sources from missions, offices, and bureaus through field support. The TB CARE management team is Cheri Vincent, Janet Phillips, and Jill Boezwinkle.
TB Task Order 2 (TB TO2)
(Awarded 7/2007; completion date 9/2011)
PATH is the prime contractor of this task order. The objectives of TB TO2 are to:
- Develop, implement, and monitor TB activities in USAID priority countries, with activities focusing on all components of the WHO-recommended STOP TB Strategy.
- Provide technical assistance to address Global Fund grant implementation bottlenecks and to help prepare TB grant proposals.
- Provide technical assistance to accelerate the introduction of advocacy, communications, and social mobilization activities for TB.
- Provide technical assistance to assist countries to respond to MDR- and extensively drug-resistant (XDR-) TB, including diagnosis, case management, infection control, strengthening of laboratory services, and introduction of new technologies.
- Design, implement, and participate in special studies, analyses, and evaluations at the direction of USAID Global or Regional Bureaus and/or Missions.
PATH’s partners are HLSP, Health Strategies International, and Initiatives, Inc. To respond to MDR- and XDR-TB, PATH has engaged the following collaborating partners: Francis J. Curry National TB Center; National Jewish Medical and Research Center; the Latvia WHO Collaborating Centre for Research and Training in Management of MDR-TB; the Foundation for Innovative New Diagnostics; and the International Council of Nurses. The Contracting Officer’s Technical Representative is Christy Hanson, and the technical adviser is Carolyn Mohan.
TREAT TB
(Awarded 9/2008; completion date 9/2013)
Technology, Research, Education and Technical Assistance for Tuberculosis (TREAT TB) is a cooperative agreement with the International Union Against Tuberculosis and Lung Disease. TREAT TB will focus on field evaluations of diagnostic techniques for TB, clinical trials and operations research to improve patient management, treatment efficacy, disease prevention, and infection control measures for TB and MDR-TB. The Agreement Officer’s Technical Representative is Christy Hanson.
Tuberculosis Control Assistance Program (TB CAP)
(Awarded 9/30/2005; completion date 3/30/2012; fully funded)
The purpose of the Tuberculosis Control Assistance Program is to improve and expand the capacity of USAID to respond to the global TB epidemic by providing state-of-the-art, context-appropriate, technically sound, and cost-effective consultation and technical assistance to high-incidence countries and USAID Missions. TB CAP supports the areas of political commitment, DOTS strengthening and expansion, and capacity building, and has a special emphasis on increasing TB-HIV integrated approaches, managing MDR-TB, expanding the involvement of new partners in DOTS at the country level (especially the private sector), and improving drug management systems. The project will scale up and expand TB control activities to meet the global targets. TB CAP is implemented by the TBCTA consortium of partners with the Royal Netherlands Tuberculosis Foundation (KNCV) as the prime. The other partners are the International Union Against Tuberculosis and Lung Disease, WHO, the American Thoracic Society, the Japanese Anti-Tuberculosis Foundation, Family Health International, MSH, and CDC.
Note: While CDC is a technical partner of the TBCTA, all funding to CDC is provided through the CDC IAA described above. KNCV serves as the Secretariat and houses the program management unit of TB CAP. It has been designed to assist with TB-HIV activities under The President's Emergency Plan for AIDS Relief (PEPFAR). The Agreement Officer’s Technical Representative is Cheri Vincent.
Tuberculosis Indefinite Quantity Contract (IQC)
(Awarded 07/13/09; completion date 07/12/2014)
The Objective of the TB IQC is to support the implementation and scale-up of the STOP TB Strategy and the global response to Multi-Drug Resistant and Extensively Drug Resistant TB. Task Orders awarded under this IQC will increase detection and successful treatment of TB, accelerate the implementation of programmatic management of drug resistant TB, and will contribute to the reduction of TB incidence and deaths in USAID priority countries. The Contracting Officer’s Technical Representative is Christy Hanson, and the technical adviser is Amy Piatek.
Tuberculosis Task Order 2015
(Awarded 9/2009; completion date 9/2015)
The objective of TB TO 2015 is to provide short and long term technical assistance to support the scale up of the STOP TB Strategy and the Global Response to Multi-Drug Resistant and Extensively Drug Resistant TB in USAID priority countries. Key technical areas of work for the Task Order are:
- Expansion and enhancement of all aspects of quality DOTS
- Programmatic management of drug resistant TB
- TB/HIV collaborative activities
- Community based approaches
- Public private partnerships/public private mix
- Advocacy, communications, and social mobilization
PATH is the prime contractor and The American Society for Microbiology (ASM); Brigham and Women's Hospital (BWH); The Foundation for Innovative New Diagnostics (FIND); Management Sciences for Health (MSH); University of California, San Francisco (UCSF); and Initiatives, Inc. are the sub contractors. Collaborating organizations are Dartmouth College, Fondazione Centro San Raffaeie del Monte Tabor, Eli Lilly MDR TB Partnership and TB Photovoice. The Contracting Officer’s Technical Representative is Christy Hanson and the technical advisor is Amy Piatek.
WHO Umbrella Grant
(Awarded 9/1999; completion date 9/30/2010)
The WHO Umbrella Grant supports broad USAID-WHO collaborations in TB, malaria and other vector-borne diseases, surveillance, research, antimicrobial resistance, maternal and child health, and HIV/AIDS at WHO headquarters in Geneva as well as regional and country offices. WHO is strong in all aspects of DOTS program design, policy dialogue, monitoring and evaluation, implementation, and advocacy, and provides assistance to countries in preparation of plans for DOTS expansion and programs to address HIV/AIDS and TB co-infection. WHO also develops (in partnership with other organizations) manuals, norms, guidelines, and training materials related to TB. The Agreement Officer’s Technical Representative is Dale Gibb, with Amy Bloom serving as the USAID TB focal point for this grant. The Umbrella Grant was replaced by the Consolidated Grant (Awarded 9/2009; completion date 9/30/2014).
TB Team
|
